This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -33.98% and 82.48%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 19.23% and 15.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Beat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Telesis Bio (TBIO) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
by Zacks Equity Research
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Will Translate Bio, Inc. (TBIO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
by Zacks Equity Research
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug
by Zacks Equity Research
Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors
Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine
by Zacks Equity Research
Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.
Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug
by Zacks Equity Research
Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.
Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study
by Zacks Equity Research
Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
by Zacks Equity Research
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.
Translate Bio, Inc. (TBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -11.11% and -12.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Will Translate Bio, Inc. (TBIO) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View
by Zacks Equity Research
Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.